The Role of Bub1 in SV40 Large T Mediated Transformation
Bub1 在 SV40 大 T 介导的转化中的作用
基本信息
- 批准号:8233029
- 负责人:
- 金额:$ 39.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAneuploidyAntigensCell AgingCellsChromosome abnormalityComplexDNA Tumor VirusesDataDominant-Negative MutationEventFamily memberGeneticGenome StabilityGenomic InstabilityGrantHumanLarge T AntigenLeadMalignant NeoplasmsMediatingMitoticMitotic spindleMonitorMutateMutationNormal CellOncogenesOncogenicPapovaviridaePhenotypePhosphorylationPhosphotransferasesPlayProtein p53ProteinsRNA InterferenceRoleSerineSimian virus 40Tumor Suppressor ProteinsViralViral Tumor AntigensViruscell transformationgenetic analysisinterestscaffoldsenescencesmall hairpin RNAtransforming virustumor
项目摘要
We have discovered an interesting set of functional interactions among three proteins: SV40 Large T
antigen (LT), the p53 tumor suppressor protein and the mitotic kinase Bub1. Bub1 is a member of the family
of checkpoint proteins that monitor the assembly of the mitotic spindle, and has been found to be mutated in
certain human cancers characterized by aneuploidy. LT antigen can also cause genomic instability by
inducing chromosomal aberrations and aneuploidy. Genetic analysis demonstrates that interaction of T
antigen with Bub1 is not required for immortalization but is necessary for T antigen to drive viral replication
and transform. Notably LT appears to act as a scaffold bringing Bub1 to p53, which then is phosphorylated
on ser37 directly by Bub1 and on ser15, indirectly by a second kinase, leading to the stabilization of p53.
Preliminary data suggests that this stabilization fo p53 is necessary for transformation by LT at least in
certain circumstances. Also of note is finding that downregulating Bub1 function either by LT expression or
by RNAi against Bub1 in the absence of LT, results in p53 dependent cellular senescence, accompanied by
phosphorylation of ser37. Recently another group has demonstrated that ras induced senescence, which
we can block with a dominant negative allele of Bub1, is also dependent on phosphorylation of p53 at serine
37. The key questions in the context of this grant are how Bub1 contributes to LT mediated replication and
transformation and to suppressing tumor formation via senescence in the absence of LT. We can imagine
several possible mechanisms: LT may use Bub1 to regulate replication and transformation via its direct
phosphorylation of p53, via Bub1 mediated phosphorylation of other targets in the LT complex or more
indirectly via by perverting Bubl's role in regulating genome stability. These mechanisms need not be
mutually exclusive. Obviously similar mechanisms may be in play as Bub1 guards "normal" cells from
transformation by promoting senescence. In this application we propose to probe each of these
mechanisms in turn.
我们发现了三种蛋白质之间有趣的功能相互作用:SV40 Large T
抗原(LT)、p53肿瘤抑制蛋白和有丝分裂激酶Bub1。Bub1是家庭的一员
检查点蛋白的监测有丝分裂纺锤体的组装,并已被发现突变,
某些以非整倍体为特征的人类癌症。LT抗原还可通过以下方式引起基因组不稳定性:
诱导染色体畸变和非整倍性。遗传分析表明,T
Bub1抗原不是永生化所必需的,但对于T抗原驱动病毒复制是必需的
和变形值得注意的是,LT似乎作为一个支架,将Bub1带到p53,然后磷酸化
通过Bub1直接作用于ser37,通过第二激酶间接作用于ser15,导致p53的稳定。
初步的数据表明,p53的这种稳定性对于LT的转化是必要的,至少在
某些情况下。同样值得注意的是,发现下调Bub1功能,无论是通过LT表达,
在没有LT的情况下,通过针对Bub1的RNAi,导致p53依赖性细胞衰老,伴随着
丝氨酸37的磷酸化。最近,另一个研究小组证明ras诱导衰老,
我们可以用Bub1的显性负性等位基因阻断,也依赖于p53丝氨酸磷酸化,
37.本研究的关键问题是Bub1如何促进LT介导的复制,
在没有LT的情况下,通过衰老来抑制肿瘤的形成。
几种可能的机制:LT可能通过Bub1直接调控复制和转化,
通过Bub1介导的LT复合物中其他靶点的磷酸化或更多,
间接地通过改变Bubl在调节基因组稳定性中的作用。这些机制不必
相互排斥。显然,类似的机制可能在起作用,因为Bub1保护“正常”细胞,
通过促进衰老进行转化。在本申请中,我们建议探测这些中的每一个
机制反过来。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS M ROBERTS其他文献
THOMAS M ROBERTS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS M ROBERTS', 18)}}的其他基金
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
9816457 - 财政年份:2019
- 资助金额:
$ 39.28万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
10238853 - 财政年份:2019
- 资助金额:
$ 39.28万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
9978752 - 财政年份:2019
- 资助金额:
$ 39.28万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
10705059 - 财政年份:2019
- 资助金额:
$ 39.28万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
10468110 - 财政年份:2019
- 资助金额:
$ 39.28万 - 项目类别:
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway
项目 2:通过 PP2A/YAP/Hippo 途径进行致癌转化
- 批准号:
10227783 - 财政年份:2017
- 资助金额:
$ 39.28万 - 项目类别:
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway
项目 2:通过 PP2A/YAP/Hippo 途径进行致癌转化
- 批准号:
9981671 - 财政年份:2017
- 资助金额:
$ 39.28万 - 项目类别:
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer
克服乳腺癌标准 HER2 导向疗法的耐药性
- 批准号:
8607754 - 财政年份:2013
- 资助金额:
$ 39.28万 - 项目类别:
Amoeboid Motility--A Cellular and Genetic Approach
变形虫运动性——细胞和遗传方法
- 批准号:
7892239 - 财政年份:2009
- 资助金额:
$ 39.28万 - 项目类别:
相似海外基金
Elucidating the effects of extra chromosome elimination in mosaic aneuploidy syndromes: Pallister-Killian syndrome as a model
阐明额外染色体消除对嵌合非整倍体综合征的影响:以 Pallister-Killian 综合征为模型
- 批准号:
10887038 - 财政年份:2023
- 资助金额:
$ 39.28万 - 项目类别:
Characterization of aneuploidy, cell fate and mosaicism in early development
早期发育中非整倍性、细胞命运和嵌合体的表征
- 批准号:
10877239 - 财政年份:2023
- 资助金额:
$ 39.28万 - 项目类别:
The impact of aneuploidy on early human development
非整倍体对人类早期发育的影响
- 批准号:
MR/X007979/1 - 财政年份:2023
- 资助金额:
$ 39.28万 - 项目类别:
Research Grant
Understanding how aneuploidy disrupts quiescence in the model eukaryote Saccharomyces cerevisiae
了解非整倍体如何破坏模型真核生物酿酒酵母的静止状态
- 批准号:
10735074 - 财政年份:2023
- 资助金额:
$ 39.28万 - 项目类别:
Preventing Age-Associated Oocyte Aneuploidy: Mechanisms Behind the Drosophila melanogaster Centromere Effect
预防与年龄相关的卵母细胞非整倍性:果蝇着丝粒效应背后的机制
- 批准号:
10538074 - 财政年份:2022
- 资助金额:
$ 39.28万 - 项目类别:
Functional evaluation of kinesin gene variants associated with female subfertility and egg aneuploidy.
与女性生育力低下和卵子非整倍性相关的驱动蛋白基因变异的功能评估。
- 批准号:
10537275 - 财政年份:2022
- 资助金额:
$ 39.28万 - 项目类别:
Using CRISPR screening to uncover aneuploidy-specific genetic dependencies
使用 CRISPR 筛选揭示非整倍体特异性遗传依赖性
- 批准号:
10661533 - 财政年份:2022
- 资助金额:
$ 39.28万 - 项目类别:
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
FASEB SRC:非整倍体的后果:纪念 Angelika Amon 的贡献
- 批准号:
10467260 - 财政年份:2022
- 资助金额:
$ 39.28万 - 项目类别:
Comparative Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos
哺乳动物胚胎非整倍性和细胞破碎动力学的比较分析
- 批准号:
10366610 - 财政年份:2022
- 资助金额:
$ 39.28万 - 项目类别: